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There was a statistically significant difference when comparing EMP levels fasting, at one
hour (p= 0.0002) and three hours (p< 0.0001) after the high fat meal. When low fat meal
was given, there was not statistical difference when comparing EMP levels fasting and
one hour and three hours after low meal.
CONCLUSION: EMP are shed in the circulation and may represent an early marker of
endothelial injury. There is a direct correlation between cholesterol and EMP levels in
healthy volunteers. A single high fat meal may lead to a detectable elevation of EMP in
the circulation even in subjects with normal fasting baseline total cholesterol.
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Background: On the base of experimental studies we formulated the hypothesis on the
development of the endothelial dysfunction: LDL cholesterol -> angiotensin AT1 receptors
(AT1R) -> oxidative stress -> endothelial dysfunction. We tested this hypothesis in
patients (pts) with stable angina. We tested also whether statin: (i) improves endothelial
function by reducing oxidative stress and (ii) that this effect is due to the reduction in
angiotensin AT1R density.
Methods: Lipid profile, platelet AT1 receptor density, serum F2-isoprostanes (marker of
oxidative stress) and nitrate + nitrite concentration, and brachial artery flow mediated
dilation (FMD, index of endothelial function) were assessed in 20 pts ( LDL cholesterol
75-230 mg%) with proven coronary heart disease, which were not on hypolipemic treat-
ment. These measurements were performed at baseline and after treatment with simvas-
tatin 40mg/24 h for 12 weeks.
Results: At baseline there was a significant linear correlation between (i) LDL cholesterol
concentration and AT1R density (r=0,55; p<0,05) (ii) AT1R density and F2-isoprostanes
concentration (r=0,62; p<0,05) and (iii) F2-isoprostanes and FMD (r= –0,65; p<0,05).
Simvastatin treatment caused a significant reduction in LDL cholesterol (152±39 vs.
89±27mg/dl; p<0,00001), AT1R density (14,42±5,42 vs 7,58±2,68 receptors/platelet;
p<0,00001), F2-isoprostanes (39,85±14,03 vs. 27,90±10,65pg/ml, p=0,017), a significant
improvement in FMD (8,85±4,80% vs 11,04±3,85%; p=0,031), and significant increase in
nitrite + nitrate (17,23±7,53 vs. 20,94±7,93uM; p=0,038). Among these simvastatin-
induced effects, only changes in AT1 receptors and F2-isoprostane concentrations
showed strong linear correlation (r=0,65; p<0,05). Conclusions: For the first time we
have shown in one study that statin causes, in addition to LDL cholesterol reduction and
endothelial function improvement, reduction in AT1R density and oxidative stress. Base-
line results suggest relationship between LDL cholesterol, AT1R density, oxidative stress
and endothelial dysfunction. Our results suggest that simvastatin-induced reduction in
oxidative stress is due to reduction in AT1R density.
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Background: Because the mechanisms of the biological effects of statin and antiotensin
converting enzyme inhibitor therapies differ, we studied the vascular responses to these
therapies in hypercholesterolemic patients.
Methods: We administered simvastatin 20 mg and placebo or ramipril 10 mg daily during
2 months with washout 2 months to 50 hypercholesterolemic patients. This study was
randomized, double-blind, placebo-controlled, crossover in design.
*=P<0.05;**=P<0.01;***=P<0.001 vs. Baseline. Data= mean±SEM.
Results: Simvastatin alone did not reduce blood pressure, however, simvastatin com-
bined with ramipril significantly reduced blood pressure after 2 months administration
compared with baseline. Compared with each baseline, simvastatin alone or combined
with ramipril significantly changed lipoproteins, and improved the percent flow-mediated
dilator response to hyperemia by 30±5% and by 53±6%, respectively (both P<0.001) and
reduced plasma levels of malondialdehyde (MDA) levels by 4±7% (P=0.026) and by
25±4% (P<0.001), respectively and MCP-1 levels by 3±3% and by 12±2%, respectively
(P=0.049 and P=0.001, respectively), and C-reactive protein levels by -4±14% and by
26±5%, respectively (P=0.036 and P<0.001, respectively), and PAI-1 antigen levels by -
7±7% and by 17±5%, respectively (P=0.828 and P<0.001, respectively). However, simv-
astatin combined with ramipril significantly changed more the percent flow-mediated dila-
tor response to hyperemia and plasma levels of MDA, MCP-1, CRP, and PAI-1 antigen
than simvastatin alone independent of lowering blood pressure.
Conclusions; Compared with simvastatin alone, simvastatin combined with ramipril sig-
nificantly improved endothelium-dependent vasodilation and fibrinolysis potential and
reduced plasma levels of oxidant stress and inflammation markers in hypercholester-
olemic patients.
Baseline1 Statin+Placebo Baseline2 Statin+Ramipril
Apo B (mg/dl) 131±4 89±3*** 129±4 92±3***
FMD (%) 4.81±0.24 6.02±0.29*** 4.56±0.22 6.58±0.25***
Nitrate (umol/l) 92±7 83±6 89±6 74±5*
MDA (υM) 1.36±0.08 1.17±0.07* 1.45±0.09 1.01±0.07***
MCP-1 (pg/ml) 194±8 178±5* 202±8 174±6***
PAI-1 (pg/ml) 64±4 63±4 68±4 53±3***
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Serum cystatin C (CysC) can generally be recommended as a marker of renal function.
We recently showed that CysC was independently of renal function positively associated
with a number of cardiovascular risk factors like age, male sex, weight, smoking and C-
reactive protein (CRP) levels. We questioned therefore whether CysC, CRP and serum
creatinine (SCr), another serum marker of renal function, carry similar prognostic signifi-
cance for mortality. Data were obtained from the PREVEND study, a longitudinal popula-
tion based cohort study in the city of Groningen, the Netherlands (n=8,592, age 28-75
yr). Preliminary results of a random sample of 6,135 subjects are presented. Median fol-
low-up time was 5.2 yrs. A total of 180 subjects died. CRP, CysC and SCr were evaluated
by dividing the whole range of measurements into 5 for sex stratified groups covering the
0 to 50th, 50 to 75th, 75 to 87.5th, 87.5 to 95th and 95 to 100th percentile. After adjustment
for age and sex, CysC , CRP but not SCr contributed independently to an increased risk
of death (P< 0.001, P< 0.0001 vs P=0.688, respectively). CysC and CRP remained both
statistically significant in the multivariate adjusted model. The figure below gives the age
and sex adjusted estimated HR (95% CI) of both CysC and CRP on the risk of death
using 0 to 50th percentile as the reference group. In conclusion, CysC is a novel, inde-
pendent and sensitive prognostic marker, a property that can not be explained by inflam-
mation or renal function. Further mechanistic studies are needed.
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Background: Spironolactone was reported to improve prognosis in patients with chronic
heart failure.However, the effect of spironolactone on coronary artery function has not be
fully elucidated. Therefore we examined the effect of spironolactone on coronary flow
with Doppler flow wire. Method: Thirty-nine patients treated with chronic heart failure
(NYHA class I-II) without significant coronary artery stenosis (% diameter stenosis<30%)
underwent Doppler flow study of the left anterior descending coronary artery. Thirteen
patients with taking spironolactone served as spironolactone group, and 26 patients with-
out taking spironolactone served as control group. Vascular reactivity was examined by
intra-coronary administrating papaverine (12.5 mg / 20 sec), acetylcholine (Ach) (3 and
30 mg / 2 min), and nitroglycerine (200 mg / 20 sec) using a Doppler guidewire. Coronary
blood flow (CBF) at control, percent increase in CBF and in coronary artery diameter
(CAD) were calculated. The comparisons between groups were analyzed with the Mann-
Whitney U test. Results: There were no significant differences between the two groups
in age, gender, coronary risk factor, ejection fraction of left ventricle, circulatory drugs,
and CBF at control between two groups. Enddiastolic dimension of left ventricle and left
ventricular mass in spironolactone group were significantly higher than those in control
group (61±6 vs. 51±9 mm. P<0.01, 515±110 vs. 400±156 g, P<0.02, respectively). The
percent increase in CBF and CAD induced by Ach in spironolactone group were signifi-
cantly greater than those in control group (89±119 vs. 5±105%, P<0.05, -8±21 vs. -
41±36%, P<0.03). Whereas, no significant differences were found in reaction induced by
papaverin and nitroglycerin between two groups. Conclusions: These results demon-
strate that spironolactone improves coronary endothelial function in patients with chronic
heart failure.
1159-196 Does Local Hypertriglyceridemia Impair Resistance 
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University of Iowa, Iowa City, IA
Background: Hypertriglyceridemia (HTG) has a modest association with cardiovascular
events. Previous studies showed that systemic HTG induces conduit vessel endothelial
dysfunction within 60 min. However, the effect of HTG on resistance vessels remains
